gefitinib has been researched along with nafamostat in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (nafamostat) | Trials (nafamostat) | Recent Studies (post-2010) (nafamostat) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 640 | 54 | 198 |
| Protein | Taxonomy | gefitinib (IC50) | nafamostat (IC50) |
|---|---|---|---|
| Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | 7.47 | |
| SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | 7.47 | |
| ubiquitin-like modifier-activating enzyme 1 | Homo sapiens (human) | 14 | |
| SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | 7.47 | |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 14 | |
| ubiquitin-conjugating enzyme E2 variant 1 isoform a | Homo sapiens (human) | 14 | |
| Prothrombin | Homo sapiens (human) | 1.9 | |
| Complement C1r subcomponent | Homo sapiens (human) | 0.8 | |
| Plasminogen | Homo sapiens (human) | 2.9 | |
| Cationic trypsin | Bos taurus (cattle) | 0.017 | |
| Serine protease hepsin | Homo sapiens (human) | 0.005 | |
| Trypsin-1 | Homo sapiens (human) | 0.017 | |
| Complement C1s subcomponent | Homo sapiens (human) | 0.029 | |
| Hepatocyte growth factor activator | Homo sapiens (human) | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Damalanka, VC; Janetka, JW; Klampfer, L; Li, S; Mahoney, MW; Primeau, T; Voss, JJLP | 1 |
1 other study(ies) available for gefitinib and nafamostat
| Article | Year |
|---|---|
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Discovery; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Macrocyclic Compounds; Mice; Receptor Protein-Tyrosine Kinases; Serine Proteinase Inhibitors; Structure-Activity Relationship | 2021 |